John I Bell Selected Research

Infections

1/2023	Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
1/2022	SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.
1/2022	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
1/2022	Epitope length variants balance protective immune responses and viral escape in HIV-1 infection.
12/2021	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
10/2021	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.
1/2021	Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.
1/2021	Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
1/2020	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel.
1/2007	First glimpse of the peptide presentation by rhesus macaque MHC class I: crystal structures of Mamu-A*01 complexed with two immunogenic SIV epitopes and insights into CTL escape.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John I Bell Research Topics

Disease

10	Infections 01/2023 - 01/2007
5	Multiple Sclerosis 09/2013 - 08/2006
3	COVID-19 01/2022 - 01/2021
2	Reinfection 01/2023 - 10/2021
2	Melanoma (Melanoma, Malignant) 01/2023 - 09/2007
2	Neoplasms (Cancer) 01/2023 - 01/2006
1	Uveal melanoma 01/2023
1	Breakthrough Infections 01/2023
1	Autoimmune Diseases (Autoimmune Disease) 11/2016
1	Demyelinating Diseases (Demyelinating Disease) 09/2013
1	Necrosis 08/2012
1	Psoriasis (Pustulosis Palmaris et Plantaris) 08/2012
1	Rheumatoid Arthritis 08/2012
1	Disease Susceptibility (Diathesis) 11/2008
1	Virus Diseases (Viral Diseases) 02/2008
1	HIV Infections (HIV Infection) 01/2007
1	Encephalomyelitis (Myeloencephalitis) 08/2006
1	Hepatitis B 06/2006
1	Severe Acute Respiratory Syndrome 11/2004
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2004
1	Narcolepsy 02/2004
1	Human Influenza (Influenza) 07/2003

Drug/Important Bio-Agent (IBA)

5	Immunoglobulin G (IgG)IBA 01/2023 - 01/2020
5	VaccinesIBA 01/2023 - 01/2021
5	BNT162 VaccineIBA 01/2022 - 01/2021
4	Peptides (Polypeptides)IBA 01/2023 - 02/2004
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 02/2008
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 07/2003
2	AntigensIBA 01/2023 - 09/2007
2	COVID-19 VaccinesIBA 01/2022 - 01/2021
1	tebentafuspIBA 01/2023
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	EpitopesIBA 01/2022
1	AntibodiesIBA 10/2021
1	ChAdOx1 nCoV-19IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2020
1	TYK2 Kinase (Tyrosine Kinase 2)IBA 11/2016
1	Tumor Necrosis Factor InhibitorsIBA 09/2013
1	Type I Tumor Necrosis Factor ReceptorsIBA 08/2012
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 08/2012
1	HLA-A Antigens (HLA-A)IBA 11/2008
1	HLA Antigens (Human Leukocyte Antigens)IBA 11/2008
1	HLA-A*02:01 antigenIBA 11/2008
1	MART-1 AntigenIBA 09/2007
1	AutoantigensIBA 09/2007
1	AIDS VaccinesIBA 01/2007
1	HLA-DR Antigens (HLA-DR)IBA 10/2006
1	HLA-DR2 Antigen (HLA DR2 Antigen)IBA 10/2006
1	Cytokine Receptors (Cytokine Receptor)IBA 06/2006
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2006
1	Histocompatibility Antigens Class IIIBA 02/2004

Therapy/Procedure

3	Therapeutics 01/2023 - 08/2006
1	Drug Therapy (Chemotherapy) 01/2023
1	Immunotherapy 01/2023